Article Information
History
- September 4, 2019.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Eddie Cano-Gamez1,2,†,
- Blagoje Soskic1,2,†,*,
- Theodoros I. Roumeliotis3,
- Ernest So3,
- Deborah J. Smyth1,2,
- Marta Baldrighi1,2,
- David Willé4,
- Nikolina Nakic5,
- Jorge Esparza-Gordillo6,
- Christopher G. C. Larminie6,
- Paola G. Bronson7,
- David F. Tough8,
- Wendy C. Rowan9,
- Jyoti S. Choudhary3 and
- Gosia Trynka1,2,*
- 1Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
- 2Open Targets, Wellcome Genome Campus, Cambridge CB10 1SA, UK
- 3Functional Proteomics, The Institute for Cancer Research, London, SW3 6JB, UK
- 4Biostatistics, GSK Medicines Research Centre, Stevenage, UK, SG1 2NY, UK
- 5Functional Genomics, Molecular Science and Technology R&D, GSK Medicines Research Centre, Stevenage, SG1 2NY, UK
- 6Human Genetics, GSK Medicines Research Centre, Stevenage, UK, SG1 2NY, UK
- 7Human Target Validation Core, RED Translational Biology, Biogen, Cambridge, MA, USA
- 8Epigenetics RU,Oncology R&D, GSK, Medicines Research Centre, Stevenage SG1 2NY, UK
- 9Novel Human Genetics, GSK R&D, Stevenage SG1 2NY, UK
- ↵*Correspondence to: Gosia Trynka (gosia{at}sanger.ac.uk) and Blagoje Soskic (bs11{at}sanger.ac.uk)
↵† These authors contributed equally to this work